NEW YORK — September 11, 2026
Quantum BioPharma Ltd. announced that the U.S. Food and Drug Administration has cleared the company to initiate a Phase 2 clinical trial of Lucid-MS, its investigational therapy for multiple sclerosis (MS). The regulatory milestone advances Lucid-MS from preclinical development into human clinical evaluation and represents an important step in Quantum BioPharma’s strategy to pursue a treatment approach focused on myelin preservation and repair rather than primarily targeting immune activity. Through its wholly owned subsidiary Lucid Psycheceuticals Inc., Quantum is developing Lucid-MS as a patented new chemical entity designed to prevent and potentially reverse myelin degradation. The company’s development strategy addresses a significant unmet need in MS, where existing therapies primarily aim to reduce inflammatory activity and slow disease progression. The FDA clearance therefore provides Quantum with an opportunity to begin generating clinical evidence for a mechanism that the company believes could complement or potentially differentiate from established MS treatment approaches.
Lucid-MS Targets Myelin Damage in Multiple Sclerosis
Lucid-MS is designed to address myelin degradation, a key pathological feature of multiple sclerosis that contributes to impaired nerve signaling and progressive loss of neurological function. Unlike conventional MS therapies that focus largely on regulating the immune system, Quantum’s candidate is being developed around the concept of protecting and restoring the myelin sheath surrounding nerve fibers. According to the company, Lucid-MS has demonstrated the ability to prevent and reverse myelin degradation in preclinical models. The proposed mechanism is particularly relevant because damage to myelin can disrupt communication between the brain, spinal cord and the rest of the body, contributing to symptoms affecting mobility, vision and physical control. Quantum estimates that nearly 2.9 million people worldwide and close to one million people in the United States live with MS. While the company’s preclinical findings provide the rationale for development, the upcoming Phase 2 program will be important for determining whether the biological effects observed in experimental models can translate into meaningful clinical benefits in people with MS.
Phase 2 Program Marks Key Clinical Development Milestone
FDA clearance of the Phase 2 program establishes the next stage of clinical development for Lucid-MS and will allow Quantum BioPharma to begin evaluating the candidate directly in patients with multiple sclerosis. The transition into human trials is particularly significant for the company because Lucid-MS has so far been supported primarily by preclinical evidence. Clinical evaluation will provide an opportunity to assess the candidate’s safety, tolerability, pharmacological effects and potential impact on disease-related outcomes in a controlled patient population. Quantum has positioned the program as an attempt to address an area that remains inadequately served by current treatment strategies: preserving or restoring neurological function after myelin damage has occurred. The company believes this could represent a differentiated therapeutic direction within the broader MS market, although the potential efficacy of Lucid-MS remains to be established through clinical studies. The FDA clearance also gives Quantum an important development catalyst as it works to advance its lead asset and establish the clinical foundation required for subsequent-stage trials.
Advertisement
Quantum BioPharma Builds Neurodegenerative Pipeline
The Lucid-MS program forms the central component of Quantum BioPharma’s strategy to develop innovative therapies for challenging neurological and metabolic disorders. The company is focused on advancing a portfolio of assets through its subsidiaries and partnerships, with Lucid Psycheceuticals responsible for the development of Lucid-MS. Quantum has also developed UNBUZZD™, an over-the-counter product that was spun out to Unbuzzd Wellness Inc., while retaining an ownership interest and royalty rights under its agreement. For Lucid-MS, however, the FDA clearance represents the company’s most important near-term clinical development opportunity. Moving into Phase 2 will allow Quantum to transition its myelin-focused approach from laboratory research toward clinical validation and potentially establish a new therapeutic strategy for MS. The upcoming trial will be a critical test of whether Lucid-MS can translate its preclinical myelin-protective and myelin-repair findings into benefits for patients, positioning clinical data generation as the company’s primary priority following FDA clearance.
Source: Quantum BioPharma press release
